EQ
Equillium·NASDAQ
--
--(--)
Market Open: --
--
--(--)
Pre-Market: --
Signals Analysis
Bullish signal 2
Bearish signal 2
Ample Liquidity
Significant Net Income Decline
Revenue Beats Expectation
EPS Below Expectations
Key Stats
0.0000DAY`S RANGE0.0000
0.000052 WK RANGE0.0000
0.0000
0.0000
--
--
--
--
--
--
--
--
--
--
--
--
--
--
0.0000
0.0000
0.0000
0.0000
About EQ
Equillium, Inc.
A clinical-stage biotechnology company that developing novel therapeutics for severe autoimmune and inflammatory disorders
2222 Avenida de la Playa, Suite 105, La Jolla, CA 92037
--
Equillium, Inc., formerly Attenuate Biopharmaceuticals, Inc., was incorporated in Delaware on March 16, 2017. The company is a clinical-stage biotechnology company that leverages a deep understanding of immunobiology to develop new therapies to treat severe autoimmune and inflammatory, or immuno-inflammatory diseases with high unmet medical needs. The company's strategy is focused on advancing the clinical development of product candidates, including potentially pursuing additional indications and acquiring new product candidates and platforms to expand the pipeline. The company intends to commercialize product candidates independently or through partnerships, or monetize the company's pipeline through strategic transactions.
Company Financials
EPS
EQ has released its 2025 Q3 earnings. EPS was reported at -0.06, versus the expected -0.22, beating expectations. The chart below visualizes how EQ has performed over recent quarters, highlighting trends in earnings surprises.
Forecast
Wall Street Opinions
Price Target
Volume Profile
Trade Flow Insight
Seasonals
Community Forum
Loading...
Related News
No articles available
